Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

medical intertrade d.o.o., dr. franje tuđmana 3, 10431 sveta nedelja, hrvatska - fluniksin - otopina za injekciju - mišićno-koštani sustav, protuupalni i antireumatski proizvodi - goveda, konja i svinja

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

medical intertrade d.o.o., dr. franje tuđmana 3, 10431 sveta nedelja, hrvatska - vitamin a ; kolekalciferol (vitamin d3) ; sav-rac-alfa-tokoferilacetat (vitamin e) ; tiaminklorid (vitamin b1) ; natrijev riboflavinfosfat (vitamin b2) ; piridoksinklorid (vitamin b6) ; nikotinamid ; dekspantenol ; cijanokobalamin (vitamin b12) - otopina za injekciju - vitamini i minerali - goveda, svinja, ovaca

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

mount trade d.o.o., trg hrvatskih branitelja 8, 43280 garešnica, hrvatska - fluniksin - otopina za injekciju - goveda i konja

Hrvatska - hrvatski - Ecolab

ecolab deutschland gmbh -

Europska Unija - hrvatski - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novatin limited, 230, second floor, eucharistic congress road, mosta, malta - sitagliptinklorid hidrat - filmom obložena tableta - urbroj: jedna tableta sadrži 100 mg sitagliptina u obliku sitagliptinklorid hidrata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novatin limited, 230, second floor, eucharistic congress road, mosta, malta - sitagliptinklorid hidrat metforminklorid - filmom obložena tableta - urbroj: jedna tableta sadrži sitagliptinklorid hidrat u količini od 50 mg sitagliptina i 1000 mg metforminklorida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novatin limited, 230, second floor, eucharistic congress road, mosta, malta - sitagliptinklorid hidrat metforminklorid - filmom obložena tableta - urbroj: jedna tableta sadrži sitagliptinklorid hidrat u količini od 50 mg sitagliptina i 850 mg metforminklorida

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Europska Unija - hrvatski - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - imunosupresivi - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).